# Adaptive (ADPT) — News

ADPT · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/adpt/news

## Recent headlines

- [Adaptive Biotechnologies Corporation: TD Cowen raises target price to $32 from $28](https://www.ainvest.com/news/adaptive-biotechnologies-corporation-td-cowen-raises-target-price-32-28-2610) — AInvest Wire, Oct 13, 2026
  TD Cowen has revised its price target for Adaptive Biotechnologies Corporation (ADPT), raising it to $32 from $28, reflecting a positive outlook on the company’s growth prospects. As of October 12, 2026, the stock closed at $25.57, representing a decline of 3.47% from the previous session. The…
- [AdvancedAdvt Ltd: Hy trading remains in line with management expectations](https://www.ainvest.com/news/advancedadvt-hy-trading-remains-line-management-expectations-2610) — AInvest Wire, Oct 12, 2026
  AdvancedAdvt Ltd (ADVT) continues to report trading performance consistent with management expectations, with no significant deviations noted in recent operations. The company recently completed a share buyback of 243,453 shares , reflecting its ongoing commitment to managing capital structure and…
- [Adaptive Biotechnologies Corp: TD Cowen raises target price to $28 from $25](https://www.ainvest.com/news/adaptive-biotechnologies-corp-td-cowen-raises-target-price-28-25-2607) — AInvest Wire, Jul 30, 2026
- [ADPT 2Q adj. EBITDA loss $0.73M, est. loss $3.75M](https://www.ainvest.com/news/adpt-2q-ebitda-loss-0-73m-est-loss-3-75m-2607) — AInvest Wire, Jul 29, 2026
  Adaptive Biotechnologies (Nasdaq: ADPT) reported a narrower-than-expected adjusted EBITDA loss of $0.73 million for the second quarter of 2024, significantly below the estimated loss of $3.75 million. The company’s MRD (Minimal Residual Disease) segment, which accounts for the majority of its…
- [Adapthealth Corp: Jefferies raises to buy from hold; raises target price to $13 from $11](https://www.ainvest.com/news/adapthealth-corp-jefferies-raises-buy-hold-raises-target-price-13-11-2607) — AInvest Wire, Jul 21, 2026
  Jefferies has upgraded its rating for Adapthealth Corp (ADPT) from "hold" to "buy," reflecting a more favorable outlook on the company’s prospects. Alongside the rating change, the firm also raised its price target to $13 from $11. The adjustment follows a recent analysis of Adapthealth’s business…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).